Top Markets
Coin of the day
Orchard Therapeutics plc Orchard Therapeutics plc

Orchard Therapeutics plc

ORTX
Rang in Aktien #18160
Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing... Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.
Aktienkurs
$16.70
Zuletzt synchronisiert: 2024-02-02
Marktkapitalisierung
$210.34M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
GB
Handel Orchard Therapeutics plc (ORTX)

Kategorie

Kursverlauf für Orchard Therapeutics plc (ORTX)
Höchster Schlusskurs: $16.70 am 2024-02-01

Niedrigster Schlusskurs: $140.00 am 2018-10-01
Kursverlauf der Aktie von Orchard Therapeutics plc von 2018 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 2.11%
2023 292.95%
2022 -67.24%
2021 -72.13%
2020 -65.44%
2019 -7.87%
2018 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.05 -8.95%
AU
$757.71 6.76%
CH